THE USE OF NEW IMMUNOMODULATORS AT SECONDARY IMMUNODEFICIENCY

В данной статье рассматривается использование нового иммуномодулятора у животных, страдающих вторичным иммунодефицитом за период последнего года. В исследованиях России и Китая в качестве новых иммуномодуляторов применялись Ganodermalucidum (Gl-PS) полисахариды и стимфорт на фоне введения циклофосфана. Иммуномодуляция играет важную роль в кроветворении. На мышах исследовали возможный механизм активации миелопоэза при миелосупрессии, вызванной циклофосфамидом. Показано, что иммуномодулятор обладает способностью корригировать количественный и субпопуляционный состав МЛ селезенки, структуру центральных и периферических органов лимфопоэза, эффекторные функции клеток иммунитета, нарушенные при введении цитостатика. В настоящем исследовании invivo и invitro обнаружили, что иммуномодуляторы избирательно связываются со стромальными клетками костного мозга, стимулирует секрецию гемопоэтических факторов роста и усиливают клоногенную активность гемопоэтических и стромальных клеток, способствуя гемопоэзу у мышей с миелосупрессией. This article reviews the use of a new immunomodulator in animals for secondary immunodeficiency in the past year. In a study in Russia and China, Ganoderma lucidum (Gl-PS) polysaccharides and stimforte were used as new immunomodulators against the background of cyclophosphamide administration. Immunomodulation plays an important role in blood formation. A possible mechanism of myelopoiesis activation in cyclophosphamide-induced myelosuppression was investigated in mice. It was shown that the immunomodulator has the ability to correct the quantitative and subpopulation composition of spleen ML, the structure of the central and peripheral organs of lymphopoiesis, the effector functions of immunity cells, impaired by the introduction of a cytostatic. In the present study, in vivo and in vitro, it was found that immunomodulators selectively bind to bone marrow stromal cells, stimulate the secretion of hematopoietic growth factors and enhance the clonogenic activity of hematopoietic and stromal cells, promoting hematopoiesis in mice with myelosuppression.

Protective Effects of Spirulina against Cyclophosphamide Induced Bone Marrow Toxicity in Mice

Spirulina Platenesis (Sp) is rich in important compounds with antioxidant effects. This study investigates the treatment and prophylactic effect of Spirulina Platenesis (Sp) against Cyclophosphamide (CP) induced bone marrow toxicity. Fifty female BALB/C mice were randomly classified into 5 equal groups: (1) Normal controls; (2) CP group: injected with 40 mg/kg for 10 days; (3) Sp group: supplied by Sp (1000 mg/kg) for 10 days; (4) Treatment group: CP + Sp; (5) Prophylactic group: Sp + CP. After 10 days, At the end of the study period, all rats were killed, blood was withdrawn, and bone marrow (BM) was subjected to investigation. Cyclophosphamide administration caused rapid dimension in CBC parameter, Bone marrow WBC count and Erythropiotein concentration in blood that have been recovered with Sp administration. According to histological analysis of the bone marrow, spirulina impaired the proliferation and hypercellularity of immature myeloid elements in the bone marrow, which CP decreased. Obviously, spirulina may with antioxidative activity reduced the oxidative stress and toxicity induced by cyclophosphamide in mouse bone marrow cells.

Fulminant Acute Disseminated Encephalomyelitis: A Remarkable Outcome with Cyclophosphamide

Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease of the central nervous system which occurs predominantly in the pediatric population. Acute treatment is high-dose intravenous glucocorticoids. Alternative treatment is usually intravenous immune globulin and/or plasma exchange. Fulminant ADEM is rare in children. Only a few cases of cyclophosphamide use in refractory ADEM have been reported. Here, we report a case of a 12-year-old girl with fulminant ADEM who was comatose and improved dramatically after cyclophosphamide administration. Cyclophosphamide treatment should be considered as a therapy in children with fulminant ADEM nonresponsive to standard therapies.